These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24510775)

  • 1. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
    Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
    Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
    Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
    Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
    Talekar M; Ouyang Q; Goldberg MS; Amiji MM
    Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ΜiR-182-5p functions as a tumor suppressor to sensitize human ovarian cancer cells to cisplatin through direct targeting the cyclin dependent kinase 6 (CDK6).
    Duan L; Yan Y; Wang G; Xing YL; Sun J; Wang LL
    J BUON; 2020; 25(5):2279-2286. PubMed ID: 33277846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
    Wu DD; Li XS; Meng XN; Yan J; Zong ZH
    Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
    Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
    J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells.
    Pellegrini E; Multari G; Gallo FR; Vecchiotti D; Zazzeroni F; Condello M; Meschini S
    Toxicol Appl Pharmacol; 2022 Jan; 434():115816. PubMed ID: 34856211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.
    Lin H; Shen L; Lin Q; Dong C; Maswela B; Illahi GS; Wu X
    Biomed Pharmacother; 2020 Mar; 123():109711. PubMed ID: 31884343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
    Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
    Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
    Xia B; Yang S; Liu T; Lou G
    Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
    Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
    Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
    Xu Y; Zhang J; Wu J; Zhong S; Li H
    Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.
    Cittelly DM; Dimitrova I; Howe EN; Cochrane DR; Jean A; Spoelstra NS; Post MD; Lu X; Broaddus RR; Spillman MA; Richer JK
    Mol Cancer Ther; 2012 Dec; 11(12):2556-65. PubMed ID: 23074172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
    Duan Z; Brakora KA; Seiden MV
    Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of miR-138-5p Sensitizes Taxol-Resistant Epithelial Ovarian Cancer Cells through Targeting Cyclin-Dependent Kinase 6.
    Liang M; Li Q; Shi S; Tian YN; Feng Y; Yang Y; Dong M; Zhang J; He J
    Gynecol Obstet Invest; 2021; 86(6):533-541. PubMed ID: 34818258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.
    Weiner-Gorzel K; Dempsey E; Milewska M; McGoldrick A; Toh V; Walsh A; Lindsay S; Gubbins L; Cannon A; Sharpe D; O'Sullivan J; Murphy M; Madden SF; Kell M; McCann A; Furlong F
    Cancer Med; 2015 May; 4(5):745-58. PubMed ID: 25684390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
    Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
    Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [miR-449b and miR-34c on inducing down-regulation of cell cycle-related proteins and cycle arrests in SKOV3-ipl cell, an ovarian cancer cell line].
    Ma Lp; Li N; He Xj; Zhang Q
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):129-33. PubMed ID: 21321636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.